Picture of Glenmark Pharmaceuticals logo

GLENMARK — Glenmark Pharmaceuticals News Story

0.000.00%
in flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

India's Glenmark posts higher quarterly profit on strong demand in N.America, Europe

Nov 14 (Reuters) - India's Glenmark Pharmaceuticals GLEN.NS reported a 72% jump in second-quarter adjusted profit on Friday, on recovery in key North American and European markets.

The drugmaker reported a consolidated net profit of 6.1 billion rupees ($69.4 million) for the quarter ended September 30, up from 3.54 billion rupees a year ago.

Total revenue from operations rose 76% to 60.47 billion rupees during the quarter.

For further earnings highlights, click here.

KEY CONTEXT

Its secondary sales growth from India formulation business grew 10.8%, while net sales from Glenmark's core businesses in North America and Europe rose 7.4% and 8.5%, respectively.

The Indian pharmaceutical market grew 7.3% in value in September, driven by strong sales in cardiovascular, anti-diabetic, and anti-infectives therapies, according to data from PharmaRack.

Peers Torrent Pharma TORP.NS posted a profit rise on strong domestic demand for its cardiovascular and anti-diabetic drugs while Mankind Pharma MNKI.NS reported a fourth straight quarter of profit decline as tax cuts hurt supply chain.

PEER COMPARISON

Valuation (next 12 months)Estimates (next 12 months)Analysts' sentiment
RICPEEV/EBITDAPrice/SalesRevenue growth(%)profit growth(%)Mean rating *# of analystsStock to price target**Div yield (%)
Glenmark Pharmaceuticals LtdGLEN.NS24.5815.49NULL10.3930.48BUY90.800.20
Mankind Pharma LtdMNKI.NS38.5425.435.9714.2518.67BUY160.850.04
Torrent Pharmaceuticals LtdTORP.NS47.0027.208.4614.4220.35BUY300.960.84
J B Chemicals and Pharmaceuticals LtdJBCH.NS32.3021.045.9111.5018.01BUY110.920.67
* The mean of analyst ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell ** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT JULY TO SEPTEMBER STOCK PERFORMANCE -- All data from LSEG -- $1 = 87.8950 Indian rupees TTEX https://tmsnrt.rs/3K1HJ5q (Reporting by Urvi Dugar in Bengaluru; Editing by Eileen Soreng) ((UrviManoj.Dugar@thomsonreuters.com; +91 9558725583;))

Recent news on Glenmark Pharmaceuticals

See all news